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doi:10.1016/j.jtcvs.2010.10.058Reply to the Editor:
We thank Emery and Krogh for
their interest in our study describing
the intermediate-term outcomes after
aortic valve replacement (AVR) with
the On-X valve (On-X Life Technolo-
gies, Inc, Austin, Tex).1 We agree that
the reporting of clinical events related
to anticoagulation is important; how-
ever, the comments of Emery and
Krogh must be taken with the follow-
ing considerations.
In our study, clinical thromboem-
bolic and hemorrhagic events were
defined in accordance with current
guidelines.2 Although the current guide-
lines do not separate thromboembolic
events into major and minor categories,
major thromboembolic events have
been extensively reported by Jamieson
and colleagues.3 Our definition of the
termmajor thromboembolism incorpo-
rated all major events (cerebral and
peripheral, inclusive of reversible is-
chemic neurologic deficits).
With reference to Table 3 in our
original article,1 there was an error
on our part and also an error in the
comment by Emery and Krogh. The720 The Journal of Thoracic and Cmajor thromboembolic events rates
for the ATS prosthesis (ATS Medical,
Inc, Minneapolis, Minn) should be
0.7%/patient-year for AVR and 0.4%/
patient-year for mitral valve replace-
ment (MVR).4 The article about the
ATSmade no mention of reversible is-
chemic neurologic deficit events, and
it also did not document whether
such events were considered minor or
major. We mistakenly reported the
minor thromboembolic event rates,
which Emery and Krogh erroneously
stated as the total thromboembolic
event rates; however, the article gave
the total AVR thromboembolic event
rate for the ATS prosthesis as 2.6%/
patient-year and the total MVR throm-
boembolic event rate as 3.0%/patient-
year. For the St JudeMedical prosthesis
(St Jude Medical, Inc, St Paul, Minn),
the major neurologic and peripheral
thromboembolic event rates should
be 1.04%/patient-year for AVR and
1.49%/patient-year for MVR5; here,
we mistakenly reported total thrombo-
embolic events. There was, however,
no mention of reversible ischemic neu-
rologic deficit events in the thrombo-
embolic event categorization in that
article.
The valve-related mortalities were
neither reported nor calculated by
us in our Table 3.1 The AVR valve-
related mortalities were similar for
the On-X and ATS valves at 0.2%/
patient-year, whereas theMVR-related
mortality was higher for the ATS
valve at 0.4%/patient-year. The valve-
related mortalities for the St JudeMed-
ical valves were 1.05%/patient-year
for AVR and 1.24%/patient-year for
MVR.5
Emery and Krogh have correctly
identified the differences associated
with the measurement of prothrombin
time versus the international normal-
ized ratio.Wedid not discuss the impact
of using prothrombin time, because this
measurement is less commonly used to
monitor anticoagulation. Our study
involved a relatively recent cohort;
anticoagulation in all patients was
therefore managed by monitoring theardiovascular Surgery c September 201international normalized ratio, in ac-
cordance with the current recommen-
dations from the American Heart
Association and the American College
of Cardiology.6
We therefore believe that our
study provides insight regarding the
intermediate-term performance of the
On-X valve in a relatively large cohort
of patients.
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